Table 1.

Summary of demographic data and of disease characteristics at baselinea

CharacteristicsPlacebo (n = 9)Satavaptan
25 mg (n = 14)50 mg (n = 12)
Age (yr)
    mean ± SD62.0 ± 18.971.1 ± 10.868.9 ± 14.0
    range34 to 8555 to 9345 to 96
Gender (male/female)2/77/74/8
SIADH origin (n [%])
    malignant tumor1 (11.1)2 (14.3)2 (16.7)
    carbamazepine2 (22.2)3 (21.4)2 (16.7)
    miscellaneous3 (33.3)4 (28.6)3 (25.0)
    idiopathic3 (33.3)5 (35.7)5 (41.7)
SNa (mmol/L)
    mean ± SD126 ± 3125 ± 6127 ± 5
    range120 to 130114 to 131115 to 131
Serum creatinine (μmol/L)
    mean ± SD64.4 ± 23.074.3 ± 19.955.0 ± 14.5
    range40.0 to 120.040.0 to 100.030.0 to 70.0
Blood urea nitrogen (mmol/L)
    mean ± SD3.9 ± 2.44.5 ± 2.54.2 ± 1.4
    range1.4 to 8.52.0 to 10.52.0 to 5.9
Serum uric acid (μmol/L)
    mean ± SD158 ± 63214 ± 132170 ± 53
    range80 to 27080 to 580100 to 270
Serum osmolality (mOsm/kg H2O)
    mean ± SD257 ± 10258 ± 14264 ± 12
    range237 to 270230 to 277241 to 284
Urinary sodium (mmol/L)
    mean ± SD69 ± 3645 ± 2777 ± 64
    range19 to 12411 to 1036 to 176
Urinary potassium (mmol/L)
    mean ± SD27 ± 1528 ± 1831 ± 24
    range10 to 609 to 724 to 74
Urinary osmolality (mOsm/kg H2O)
    mean ± SD428 ± 198432 ± 168451 ± 206
    range184 to 848257 to 794187 to 657
  • a SIADH, syndrome of inappropriate antidiuretic hormone secretion; SNa, serum sodium.